Sean McCutcheon
Stock Analyst at Raymond James
(1.61)
# 3,466
Out of 5,124 analysts
11
Total ratings
45.45%
Success rate
-0.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Strong Buy | $72 → $76 | $79.65 | -4.58% | 2 | Oct 17, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $6.03 | +99.00% | 1 | Jul 11, 2025 | |
| JANX Janux Therapeutics | Initiates: Outperform | $65 | $13.80 | +371.01% | 1 | Jul 11, 2025 | |
| CMPX Compass Therapeutics | Reinstates: Outperform | $9 | $5.37 | +67.60% | 1 | Jul 1, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Outperform | $11 | $2.43 | +352.67% | 1 | Jul 1, 2025 | |
| ENGN enGene Holdings | Initiates: Outperform | $23 | $9.03 | +154.71% | 1 | Nov 27, 2024 | |
| XNCR Xencor | Maintains: Strong Buy | $58 → $40 | $15.31 | +161.27% | 1 | Jun 14, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $92 → $70 | $63.54 | +10.17% | 2 | May 23, 2024 | |
| LEGN Legend Biotech | Initiates: Outperform | $86 | $21.74 | +295.58% | 1 | Mar 13, 2024 |
Revolution Medicines
Oct 17, 2025
Maintains: Strong Buy
Price Target: $72 → $76
Current: $79.65
Upside: -4.58%
Vir Biotechnology
Jul 11, 2025
Initiates: Outperform
Price Target: $12
Current: $6.03
Upside: +99.00%
Janux Therapeutics
Jul 11, 2025
Initiates: Outperform
Price Target: $65
Current: $13.80
Upside: +371.01%
Compass Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $9
Current: $5.37
Upside: +67.60%
Black Diamond Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $11
Current: $2.43
Upside: +352.67%
enGene Holdings
Nov 27, 2024
Initiates: Outperform
Price Target: $23
Current: $9.03
Upside: +154.71%
Xencor
Jun 14, 2024
Maintains: Strong Buy
Price Target: $58 → $40
Current: $15.31
Upside: +161.27%
Cytokinetics
May 23, 2024
Maintains: Outperform
Price Target: $92 → $70
Current: $63.54
Upside: +10.17%
Legend Biotech
Mar 13, 2024
Initiates: Outperform
Price Target: $86
Current: $21.74
Upside: +295.58%